Status:

UNKNOWN

Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns

Lead Sponsor:

American Scitech International

Collaborating Sponsors:

Johnson & Johnson

Conditions:

Burns

Electric Burns

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

Platelet Derived Growth Factor (PDGF) is a potent mitogen for a wide range of cell types including fibroblasts, smooth muscle and connective tissue. Recombinant human platelet derived growth factor (R...

Detailed Description

The R-Pdf/Gbb is recombinant human platelet-derived growth factor. It has been demonstrated that rhPDGF is effective in enhancing wound healing. OBJECTIVE: The primary objective of the study is to de...

Eligibility Criteria

Inclusion

  • Patients willing to sign Informed consent.
  • Patients of both genders.
  • Patients between ages of 18 to 75 years.
  • Patients having third degree wounds caused by thermal and electrical burns.
  • Patients not willing to undergo skin grafting.
  • Patients with multiple wounds are considered but each burn wound surface area will be less than 1-8 cm2.
  • Wounds with adequate perfusion as assessed with the help of laser Doppler flowmeter.

Exclusion

  • Patient refuses to sign informed consent.
  • Burnt wounds severity less/more than III degree (i.e. I, II, IV degree burns).
  • Patients having known neoplasm at the site of application.
  • Patients with low serum proteins.
  • Patients with uncontrolled hyperglycemia.
  • Patients who are taking Ibuprofen.
  • Patients with known hypersensitivity to parabens.
  • All other burns except thermal and electrical burns.
  • Neurological or psychiatric pathologies.
  • Women who are pregnant or nursing and women of child bearing age, who are not taking contraceptives or not willing to use them for the period of treatment.
  • Local or systemic infection
  • Conditions that would interfere with wound healing (diabetes, hypertension, inflammatory diseases treated by corticoids)

Key Trial Info

Start Date :

July 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2012

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00812513

Start Date

July 1 2011

End Date

April 1 2012

Last Update

July 20 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Saint. Barnabas Medical Center, The Burn Center

Livingston, New Jersey, United States, 07039